Optimi Health Appoints Chief Clinical Development Officer
Analysis based on 8 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026
The appointment is a modest positive for Optimi Health as it adds clinical trial leadership ahead of two planned psychedelic therapy trials, but it is unlikely to move broader markets. The news is company-specific and has negligible impact on overall market sentiment.
Optimi Health, a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announced the appointment of Michael Blough, Ph.D., as its Chief Clinical Development Officer, a newly created position. Dr. Blough has worked with Optimi on clinical trial applications since 2022 and has significant experience leading Canada — Health Canada-authorized clinical trials. In his new role, he will oversee Optimi's clinical development strategy and operations, including a planned Phase 2 clinical trial evaluating naturally derived psilocybin-assisted psychotherapy for major depressive disorder and a Phase 3 clinical trial evaluating MDMA-assisted psychotherapy for PTSD. Both trials are expected to begin enrolling patients next year. Dr. Blough will be responsible for protocol execution, site activation, Canada — Health Canada interactions, and the datasets intended to support registration of the company's drug products. He brings more than 20 years of experience directing research programs spanning bench science, pre-clinical studies, and clinical trials, including leading the development and Canada — Health Canada authorization of multiple psilocybin and MDMA trials for mental health conditions. Before entering psychedelic medicine, he spent 15 years in brain cancer research, publishing over 30 peer-reviewed papers on glioblastoma, and led a seven-year national initiative funded by the Terry Fox Research Institute. Optimi Health is a Canada — Health Canada-licensed manufacturer producing validated MDMA and botanical psilocybin drug products at GMP-compliant facilities in British Columbia, Canada, with products prescribed in Australia under its Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard